Heart failure & cardiomyopathies
Long-Term Durability of Acoramidis Efficacy in Transthyretin Amyloid Cardiomyopathy: Open-Label Extension of the ATTRibute-CM Randomized Clinical Trial
Authors' conclusion
In this OLE of the ATTRibute-CM randomized clinical trial, early and continuous acoramidis treatment resulted in sustained incremental reductions in ACM, CVM, and first CVH through month 54.
Study context
- Population
- Adults (18–90 years) with ATTR-CM who completed ATTRibute-CM632 randomised in parent trial
- Participants
- 389 adults
- Comparison
- Continuous acoramidis vs placebo to acoramidis
- Continuous acoramidisn = 263
- Placebo to acoramidisn = 126reference
- Primary endpoint
- Time to all-cause mortality (ACM), CVM and first CV hospitalization
- Follow-up
- Month 54
Methodological detailsinternational, multicentre, ongoing
- International
- Multicentre
- Ongoing
Primary result
As reported in the abstract
through month 54
Continuous acoramidis vs Placebo to acoramidisHazard ratio (95% CI)P value
ACM
0.55(0.42–0.74)
P < 0.001CVM
0.51(0.36–0.71)
P < 0.001First CV hospitalization
0.53(0.42–0.69)
P < 0.001Further findings
NT-proBNP, sTTR, KCCQ-OS, 6MWD · through month 54
- Continuous acoramidis stabilized increases in NT-proBNP, sustained higher sTTR levels, and stabilized KCCQ-OS score and 6MWD
- Switching from placebo to acoramidis at month 30 associated with stabilization of NT-proBNP and KCCQ-OS score and improvements in sTTR and 6MWD
Original publication
Long-Term Durability of Acoramidis Efficacy in Transthyretin Amyloid Cardiomyopathy: Open-Label Extension of the ATTRibute-CM Randomized Clinical Trial. JAMA Cardiol. Published 1 May 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →